Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. (June 2022)

• Record Type: Journal Article
• Authors: Zabalza, Ana; Arrambide, Georgina; Otero-Romero, Susana; Pappolla, Agustín; Tagliani, Paula; López-Maza, Samuel; Cárdenas-Robledo, Simón; Esperalba, Juliana; Fernández-Naval, Candela; Martínez-Gallo, Monica; Castillo, Mireia; Bonastre, Mercè; Resina-Salles, Mireia; Bertran, Jordina; Rodriguez-Barranco, Marta; Carbonell-Mirabent, Pere; Gonzalez, Marina; Merchan, Miguel; Quiroga-Varela, Ana; Miguela, Albert; Gómez, Imma; Álvarez, Gary; Robles, René; Perez del Campo, Dúnia; Queralt, Xavier; Soler, Maria José; Agraz, Irene; Martinez-Valle, Fernando; Rodríguez-Acevedo, Breogán; Midaglia, Luciana; Vidal-Jordana, Ángela; Cobo-Calvo, Álvaro; Tur, Carmen; Galan, Ingrid; Castillo, Joaquín; Río, Jordi; Espejo, Carmen; Comabella, Manuel; Nos, Carlos; Sastre-Garriga, Jaume; Ramió-Torrentà, Lluís; Tintoré, Mar; Montalban, Xavier;
• Is Part Of: Multiple sclerosis. Volume 28:Number 7(2022)
• Page Start: 1138
• Page End: 1145
• Publication Date: 2022-06
• Subjects: COVID-19 -- SARS-CoV-2 -- multiple sclerosis -- disease-modifying therapy -- humoral response -- cellular response; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/13524585221089540
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear. Objectives: We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID). Methods: Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers. Results: 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies. Conclusion: Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.